T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma

Summary

The purpose of this study is to assess wether it is safe and feasible to treat patients with tumor infiltrating lymphocytes that have been silenced for PD-1, using CRISPR-Cas9.

Timeline

Start

2024-12-16

Primary completion

2027-01-01

Completion

2028-01-01

Publications

• Background Chamberlain CA, Bennett EP, Kverneland AH, Svane IM, Donia M, Met O. Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy. Mol Ther Oncolytics. 2022 Jan 10;24:417-428. doi: 10.1016/j.omto.2022.01.004. eCollection 2022 Mar 17.

Drugs

Indications